Next, as we had identified the molecular profile of unfavorable BCR-related prognosis comprising ESR1 and MMP3, we investigated the downstream biological consequences possibly reflecting the increased risk of PRAD recurrence; therefore, we focused on the transcriptional effectors of ESR1 involved in the EMT (41 genes; see Materials), considered a key mechanism for the relapse of the disease and invasive potential. The gene discussed is ESR1; the disease is prostate adenocarcinoma.